{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:45:54Z","timestamp":1770835554168,"version":"3.50.1"},"reference-count":257,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T00:00:00Z","timestamp":1652227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Portuguese Foundation for Science and Technology (FCT)","award":["PTDC\/MED-ONC\/29402\/2017"],"award-info":[{"award-number":["PTDC\/MED-ONC\/29402\/2017"]}]},{"name":"the Portuguese Foundation for Science and Technology (FCT)","award":["UIDP\/04138\/2020"],"award-info":[{"award-number":["UIDP\/04138\/2020"]}]},{"name":"the Portuguese Foundation for Science and Technology (FCT)","award":["UIDB\/04138\/2020"],"award-info":[{"award-number":["UIDB\/04138\/2020"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>One of the biggest challenges in neuro-oncology is understanding the complexity of central nervous system tumors, such as gliomas, in order to develop suitable therapeutics. Conventional therapies in malignant gliomas reconcile surgery and radiotherapy with the use of chemotherapeutic options such as temozolomide, chloroethyl nitrosoureas and the combination therapy of procarbazine, lomustine and vincristine. With the unraveling of deregulated cancer cell signaling pathways, targeted therapies have been developed. The most affected signaling pathways in glioma cells involve tyrosine kinase receptors and their downstream pathways, such as the phosphatidylinositol 3-kinases (PI3K\/AKT\/mTOR) and mitogen-activated protein kinase pathways (MAPK). MAPK pathway inhibitors include farnesyl transferase inhibitors, Ras kinase inhibitors and mitogen-activated protein extracellular regulated kinase (MEK) inhibitors, while PI3K\/AKT\/mTOR pathway inhibitors are divided into pan-inhibitors, PI3K\/mTOR dual inhibitors and AKT inhibitors. The relevance of the immune system in carcinogenesis has led to the development of immunotherapy, through vaccination, blocking of immune checkpoints, oncolytic viruses, and adoptive immunotherapy using chimeric antigen receptor T cells. In this article we provide a comprehensive review of the signaling pathways underlying malignant transformation, the therapies currently used in the treatment of malignant gliomas and further explore therapies under development, including several ongoing clinical trials.<\/jats:p>","DOI":"10.3390\/ijms23105351","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T10:19:46Z","timestamp":1652264386000},"page":"5351","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Therapeutic Options in Neuro-Oncology"],"prefix":"10.3390","volume":"23","author":[{"given":"Mariana","family":"Afonso","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisbon, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8493-4649","authenticated-orcid":false,"given":"Maria Alexandra","family":"Brito","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisbon, Portugal"},{"name":"Research Institute for Medicines (iMed), Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisbon, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Lisak, R.P., Truong, D., Carroll, W.M., and Bhidayasiri, R. (2016). International Neurology-Neuro-Oncology Overview, John Wiley & Sons, Ltd.. [2nd ed.].","DOI":"10.1002\/9781118777329"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2018.03.016","article-title":"Next generation neuro-oncology","volume":"96","author":"Weller","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_3","first-page":"1114","article-title":"Central nervous system cancers clinical practice guidelines in oncology","volume":"3","author":"Brem","year":"2013","journal-title":"JNCCN J. Natl. Compr. Cancer Netw."},{"key":"ref_4","unstructured":"(2021, February 28). Acoustic Neuroma. Available online: https:\/\/www.mayoclinic.org\/diseases-conditions\/acoustic-neuroma\/symptoms-causes\/syc-20356127."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nec.2018.08.010","article-title":"Epidemiology and Molecular Epidemiology","volume":"30","author":"Bauchet","year":"2019","journal-title":"Neurosurg. Clin. N. Am."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/nan.12432","article-title":"WHO 2016 Classification of Gliomas","volume":"44","author":"Wesseling","year":"2017","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.addr.2021.01.012","article-title":"Frontiers in the treatment of glioblastoma: Past, present and emerging","volume":"171","author":"Janjua","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0140-6736(18)30990-5","article-title":"Primary brain tumours in adults","volume":"392","author":"Lapointe","year":"2018","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2176\/nmc.ra.2017-0010","article-title":"The 2016 WHO classification of tumours of the central nervous system: The major points of revision","volume":"57","author":"Komori","year":"2017","journal-title":"Neurol. Med.-Chir."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/neuonc\/noab120","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: Clinical implications","volume":"23","author":"Wen","year":"2021","journal-title":"Neuro-Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s13311-017-0529-8","article-title":"Neuro-Oncology: Current Concepts and Emerging Therapeutics","volume":"14","author":"Nabors","year":"2017","journal-title":"Neurotherapeutics"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e187","DOI":"10.1016\/j.lpm.2018.04.015","article-title":"Di Quarterly Medical Review The 2016 World Health Organization classification of tumours of the central nervous system","volume":"47","author":"Villa","year":"2018","journal-title":"La Presse M\u00e9d."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1212\/CON.0000000000000536","article-title":"2016 World Health Organization Classification of Central Nervous System Tumors","volume":"23","author":"Wen","year":"2017","journal-title":"CONTINUUM Lifelong Learn. Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol."},{"key":"ref_15","first-page":"353","article-title":"Carcinogenesis: Evolution of Concepts","volume":"74","author":"Lichtenstein","year":"2009","journal-title":"Biochemistry"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1080\/01926230490426507","article-title":"Cancer Therapeutics: Understanding the Mechanism of Action","volume":"32","author":"Cattley","year":"2004","journal-title":"Toxicol. Pathol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1586\/14737140.7.11.1581","article-title":"Cancer stem cells and brain tumors: Uprooting the bad seeds","volume":"7","author":"Lee","year":"2007","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1600-0463.2005.apm_371.x","article-title":"Stem cell biology and the cellular pathways of carcinogenesis","volume":"113","author":"Gudjonsson","year":"2005","journal-title":"Apmis"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1097\/MD.0000000000004765","article-title":"Cancer stem cell signaling pathways","volume":"95","author":"Matsui","year":"2016","journal-title":"Medicine"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1111\/j.1742-4658.2009.07177.x","article-title":"Brain angiogenesis: Mechanism and Therapeutic Intervention in Brain Tumors","volume":"276","author":"Kim","year":"2009","journal-title":"FEBS J."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Thakur, C. (2018). Nanotechnology-Based Targeted Drug Delivery Systems for Brain Tumors: Angiogenesis in Brain Tumors, Academic Press.","DOI":"10.1016\/B978-0-12-812218-1.00002-6"},{"key":"ref_22","first-page":"3297","article-title":"Developmental Signaling Pathways in Brain Tumor-Derived Stem-Like Cells","volume":"236","author":"Clark","year":"2007","journal-title":"Dev. Dyn. Off. Publ. Am. Assoc. Anat."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1586\/14737140.3.5.595","article-title":"Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: Growth factor and Ras signaling pathways","volume":"3","author":"Newton","year":"2003","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.3390\/cancers3033242","article-title":"Aberrant Signaling Pathways in Glioma","volume":"3","author":"Nakada","year":"2011","journal-title":"Cancers"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/cncr.22741","article-title":"Molecularly Targeted Therapy for Malignant Glioma","volume":"110","author":"Sathornsumetee","year":"2007","journal-title":"Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.pmrj.2015.10.012","article-title":"Update on Brain Tumors: New Developments in Neuro-oncologic Diagnosis and Treatment, and Impact on Rehabilitation Strategies","volume":"8","author":"Shahpar","year":"2016","journal-title":"PMR"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/B978-0-444-52138-5.00018-9","article-title":"Molecularly Targeted Therapy in Neuro-Oncology","volume":"Volume 104","author":"Aminoff","year":"2012","journal-title":"Handbook of Clinical Neurology"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Tilak, M., Holborn, J., New, L.A., Lalonde, J., and Jones, N. (2021). Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22041831"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/RMR.0000000000000112","article-title":"De Cell Signaling Pathways in Brain Tumors","volume":"26","author":"Harrison","year":"2017","journal-title":"Top. Magn. Reson. Imaging"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13148-018-0598-5","article-title":"Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells","volume":"11","author":"Was","year":"2019","journal-title":"Clin. Epigenet."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.pmch.2014.11.002","article-title":"Recent Advances in Cancer Therapeutics","volume":"Volume 54","author":"Lawton","year":"2015","journal-title":"Progress in Medicinal Chemistry"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"a018713","DOI":"10.1101\/cshperspect.a018713","article-title":"Erasers of Histone Acetylation: The Histone Deacetylase Enzymes","volume":"6","author":"Seto","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"101896","DOI":"10.1016\/j.ctrv.2019.101896","article-title":"Molecular targeted therapy of glioblastoma","volume":"80","author":"Preusser","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Ellert-miklaszewska, A., Poleszak, K., and Pasierbinska, M. (2020). Integrin Signaling in Glioma Pathogenesis: From Biology to Therapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21030888"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1747-1028-7-18","article-title":"The ubiquitin-proteasome system in glioma cell cycle control","volume":"7","author":"Vlachostergios","year":"2012","journal-title":"Cell Div."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s10014-020-00377-9","article-title":"Glioblastomas harboring gene fusions detected by next-generation sequencing","volume":"37","author":"Na","year":"2020","journal-title":"Brain Tumor Pathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/jnen\/nly022","article-title":"Targetable gene fusions associate with the IDH wild-type astrocytic lineage in adult gliomas","volume":"77","author":"Ferguson","year":"2018","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"715206","DOI":"10.3389\/fneur.2021.715206","article-title":"Fusion Genes Altered in Adult Malignant Gliomas","volume":"12","author":"You","year":"2021","journal-title":"Front. Neurol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3322\/caac.21613","article-title":"Management of Glioblastoma: State of the Art and Future Directions","volume":"70","author":"Tan","year":"2020","journal-title":"CA A Cancer J. Clin."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s13046-019-1269-x","article-title":"MET in glioma: Signaling pathways and targeted therapies","volume":"38","author":"Cheng","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/s41416-020-0814-x","article-title":"IDH mutation in glioma: Molecular mechanisms and potential therapeutic targets","volume":"122","author":"Han","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_42","first-page":"1155","article-title":"Novel IDH1 Targeted Glioma Therapies","volume":"33","author":"Nguyen","year":"2020","journal-title":"CNS Drugs."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11864-016-0418-0","article-title":"Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future","volume":"17","author":"Chen","year":"2016","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/annonc\/mdx106","article-title":"Glioblastoma targeted therapy: Updated approaches from recent biological insights","volume":"28","author":"Touat","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/neuonc\/nos298","article-title":"Monocarboxylate transporters (MCTs) in gliomas: Expression and exploitation as therapeutic targets","volume":"15","author":"Honavar","year":"2013","journal-title":"Neuro-Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1016\/j.bbamcr.2016.03.013","article-title":"Monocarboxylate transporters in the brain and in cancer","volume":"1863","author":"Sboarina","year":"2016","journal-title":"Biochim. Biophys. Acta (BBA)-Mol. Cell Res."},{"key":"ref_47","first-page":"1967","article-title":"An overview of MCT1 and MCT4 in GBM: Small molecule transporters with large implications","volume":"8","author":"Park","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Khalyfa, A., Qiao, Z., Raju, M., Shyu, C.R., Coghill, L., Ericsson, A., and Gozal, D. (2021). Monocarboxylate transporter-2 expression restricts tumor growth in a murine model of lung cancer: A multi-omic analysis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910616"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1124\/pr.119.018762","article-title":"Monocarboxylate Transporters (SLC16): Function, Regulation, and Role in Health and Disease","volume":"72","author":"Felmlee","year":"2020","journal-title":"Pharmacol. Rev."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Becker, H.M., and Deitmer, J.W. (2021). Proton Transport in Cancer Cells: The Role of Carbonic Anhydrases. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22063171"},{"key":"ref_51","unstructured":"(2021, June 01). National Cancer Institute Cancer Drug Resistance: Unraveling Its Complexity, Available online: https:\/\/www.cancer.gov\/research\/annual-plan\/scientific-topics\/drug-resistance."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/17425247.2019.1676227","article-title":"Novel therapeutics for brain tumors: Current practice and future prospects","volume":"17","author":"Kedda","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"339","DOI":"10.15171\/apb.2017.041","article-title":"The Different Mechanisms of Cancer Drug Resistance: A Brief Review","volume":"7","author":"Mansoori","year":"2017","journal-title":"Adv. Pharm. Bull."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s43440-020-00138-7","article-title":"Drug resistance in cancer: Mechanisms and tackling strategies","volume":"72","author":"Haider","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: An evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s12035-012-8244-2","article-title":"Neurovascular Unit: A Focus on Pericytes","volume":"45","author":"Brites","year":"2012","journal-title":"Mol. Neurobiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.brainresrev.2010.05.003","article-title":"Looking at the blood\u2013brain barrier: Molecular anatomy and possible investigation approaches","volume":"64","author":"Cardoso","year":"2010","journal-title":"Brain Res. Rev."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"E3","DOI":"10.3171\/2011.10.FOCUS11252","article-title":"Focused ultrasound disruption of the blood brain barrier: A new frontier for therapeutic delivery in molecular neuro-oncology","volume":"32","author":"Etame","year":"2014","journal-title":"Neurosurg. Focus"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"563840","DOI":"10.3389\/fonc.2020.563840","article-title":"Blood-Brain Barrier Disruption in Neuro-Oncology: Strategies, Failures, and Challenges to Overcome","volume":"10","author":"Karmur","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Acree, W. (2012). Blood Brain Barrier Permeation. Toxicity and Drug Testing, IntechOpen.","DOI":"10.5772\/1976"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_62","unstructured":"Karisa, C., and Schreck, S.A.G. (2021, March 14). Role of Temozolomide in the Treatment of Cancers Involving the Central Nervous System. Available online: https:\/\/www.cancernetwork.com\/view\/role-temozolomide-cns."},{"key":"ref_63","first-page":"2585","article-title":"Temozolomide and treatment of malignant glioma","volume":"6","author":"Friedman","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.pmr.2016.08.005","article-title":"Brain Tumors and Metastases","volume":"28","author":"Vargo","year":"2017","journal-title":"Phys. Med. Rehabil. Clin."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Barciszewska, A.M., Gurda, D., G\u0142odowicz, P., Nowak, S., and Naskr\u0119t-Barciszewska, M.Z. (2015). A new epigenetic mechanism of temozolomide action in glioma cells. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0136669"},{"key":"ref_66","unstructured":"(2021, June 04). RCM-Temodal. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/temodal-epar-product-information_pt.pdf."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jelechem.2013.07.011","article-title":"Temozolomide chemical degradation to 5-aminoimidazole-4-carboxamide\u2013Electrochemical study","volume":"704","author":"Lopes","year":"2013","journal-title":"J. Electroanal. Chem."},{"key":"ref_68","unstructured":"(2021, March 14). 3D Conformer Image of CID 5394 (Temozolomide), Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Temozolomide."},{"key":"ref_69","unstructured":"(2021, March 14). 3D Conformer Image of CID 9679 [5-Aminoimidazole-4-carboxamide], Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/9679."},{"key":"ref_70","unstructured":"(2021, March 14). 3D Conformer Image of CID 76953 [5-(3-Methyl-1-triazeno)imidazole-4-carboxamide], Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/5-_3-Methyl-1-triazeno_imidazole-4-carboxamide."},{"key":"ref_71","unstructured":"(2021, June 04). 3D Conformer Image of CID 115287 (Methanediazonium), Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Methanediazonium."},{"key":"ref_72","unstructured":"(2022, February 10). 3D Conformer Image of CID 280 [Carbon dioxide], Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/280."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.amjmed.2017.12.039","article-title":"Brain Tumors","volume":"131","author":"Lee","year":"2018","journal-title":"Am. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41568-019-0224-7","article-title":"Brain immunology and immunotherapy in brain tumours","volume":"20","author":"Sampson","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_75","unstructured":"Avenda\u00f1o, C., and Menendez, J.C. (2015). Medicinal Chemistry of Anticancer Drugs, Elsevier."},{"key":"ref_76","unstructured":"Antonini, I., Lin, T.S., Cosby, L.A., Dai, Y.R., and Sartorelli, A.C. (2014). Journal of Medicinal Chemistry: DNA-Interactive Agents, ACS Publications."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.4161\/cc.20862","article-title":"Chloroethylnitrosourea-induced cell death and genotoxicity","volume":"11","author":"Nikolova","year":"2012","journal-title":"Cell Cycle"},{"key":"ref_78","unstructured":"(2021, June 10). 3D Conformer Image of CID 75394 [1-(2-Chloroethyl)-1-nitrosourea], Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/75394."},{"key":"ref_79","unstructured":"(2021, June 10). 3D Conformer Image of CID 23662428 [cis-(2-Chloroethyl)hydroxydiazene potassium salt], Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/23662428."},{"key":"ref_80","unstructured":"(2021, June 10). 3D Conformer Image of CID 637659 [Isocyanatocyclopropane], Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/637659."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11910-015-0611-8","article-title":"Nitrosoureas in the Management of Malignant Gliomas","volume":"16","author":"Brandes","year":"2016","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bbcan.2017.01.004","article-title":"Chloroethylating nitrosoureas in cancer therapy: DNA damage, repair and cell death signaling","volume":"1868","author":"Nikolova","year":"2017","journal-title":"Biochim. Et Biophys. Acta (BBA)-Rev. Cancer"},{"key":"ref_83","unstructured":"Bethesda, M., and PDQ\u00ae Adult Treatment Editorial Board (2021, June 10). PDQ Adult Central Nervous System Tumors Treatment, Available online: https:\/\/www.cancer.gov\/types\/brain\/hp\/adult-brain-treatment-pdq."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","article-title":"A view on drug resistance in cancer","volume":"575","author":"Vasan","year":"2019","journal-title":"Nature"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1310\/hpj5202-98","article-title":"Procarbazine, Lomustine, and Vincristine (PCV) Regimen for Central Nervous System Tumors","volume":"52","author":"Solimando","year":"2017","journal-title":"Hosp. Pharm."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2217\/cns.15.36","article-title":"Procarbazine, lomustine and vincristine or temozolomide: Which is the better regimen?","volume":"4","author":"Lassman","year":"2015","journal-title":"CNS Oncol."},{"key":"ref_87","unstructured":"Procarbazine (2022, February 26). CCO Formul., Available online: https:\/\/www.cancercareontario.ca\/en\/drugformulary\/drugs\/monograph\/44016."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Vardanyan, R.S., and Hruby, V.J. (2006). Synthesis of Essential Drugs, Elsevier.","DOI":"10.1016\/B978-044452166-8\/50036-4"},{"key":"ref_89","unstructured":"Avenda\u00f1o, C., and Men\u00e9ndez, C. (2015). Medicinal Chemistry of Anticancer Drugs, Elsevier. [2nd ed.]."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11912-019-0783-5","article-title":"Evidence-Based Practice: Temozolomide Beyond Glioblastoma","volume":"21","author":"Chua","year":"2019","journal-title":"Curr. Oncol. Rep."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1093\/neuonc\/noz033","article-title":"Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus","volume":"21","author":"Schiff","year":"2019","journal-title":"Neuro-Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1002\/cncr.31371","article-title":"Regimen of Procarbazine, Lomustine, and Vincristine Versus Temozolomide for Gliomas","volume":"124","author":"Wick","year":"2018","journal-title":"Cancer"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/onco.13701","article-title":"Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort","volume":"26","author":"Hospital","year":"2021","journal-title":"Oncologist"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"17040","DOI":"10.1038\/sigtrans.2017.40","article-title":"Targeting cellular pathways in glioblastoma multiforme","volume":"2","author":"Pearson","year":"2017","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1158\/1078-0432.CCR-18-0855","article-title":"Targeted Therapies for Brain Tumors: Will They Ever Deliver ?","volume":"24","author":"Vogelbaum","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Bolcaen, J., Nair, S., Driver, C.H.S., Boshomane, T.M.G., Ebenhan, T., and Vandevoorde, C. (2021). Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma. Pharmaceuticals, 14.","DOI":"10.3390\/ph14070626"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1215\/S1522851705000451","article-title":"Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma 1","volume":"8","author":"Prados","year":"2006","journal-title":"Neuro-Oncol."},{"key":"ref_98","first-page":"1268","article-title":"Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034","volume":"27","author":"Brandes","year":"2021","journal-title":"J. Neurooncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11060-009-0067-2","article-title":"Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme","volume":"98","author":"Peereboom","year":"2010","journal-title":"J. Neurooncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ijrobp.2010.01.070","article-title":"Phase II evaluation of gefitinib in patients with newly diagnosed grade 4 astrocytoma: Mayo\/North Central Cancer Treatment Group study N0074","volume":"80","author":"Uhm","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s11060-009-9950-0","article-title":"Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma","volume":"96","author":"Reardon","year":"2010","journal-title":"J. Neurooncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1158\/2159-8290.CD-11-0284","article-title":"Differential Sensitivity of Glioma-versus Lung Cancer-specific EGFR mutations to EGFR Kinase Inhibitors","volume":"2","author":"Vivanco","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s13046-019-1264-2","article-title":"Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells","volume":"38","author":"Vengoji","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"vi70","DOI":"10.1093\/neuonc\/noab196.271","article-title":"CTNI-46. Phase I Open-Label, Single-Center, Dose Escalation Study (Nct02423525) Of Pulsatile Afatinib In Patients With Brain Cancer","volume":"23","author":"Wagle","year":"2021","journal-title":"Neuro-Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/PO.19.00295","article-title":"Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma","volume":"4","author":"Chi","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1124\/dmd.118.084210","article-title":"Brain distribution of a panel of epidermal growth factor receptor inhibitors using cassette dosing in wild-type and ABCB1\/ABCG2-deficient mice","volume":"47","author":"Kim","year":"2019","journal-title":"Drug Metab. Dispos."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1158\/1078-0432.CCR-19-1871","article-title":"Preclinical comparison of the blood-brain barrier permeability of osimertinib with other EGFR TKIs","volume":"27","author":"Colclough","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s13046-019-1235-7","article-title":"The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma","volume":"38","author":"Liu","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.18632\/oncotarget.27599","article-title":"Efficacy of osimertinib against EGFRvIII+glioblastoma","volume":"11","author":"Chagoya","year":"2020","journal-title":"Oncotarget"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Lu, S., Wang, Q., Zhang, G., Dong, X., Yang, C.-T., Song, Y., Chang, G.-C., Lu, Y., Pan, H., and Chiu, C.-H. (2022, April 17). Abstract CT190: A Multicenter, Open-Label, Single-Arm, Phase II Study: The Third Generation Egfr Tyrosine Kinase Inhibitor Almonertinib for Pretreated Egfr t790m-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (APOLLO). Available online: https:\/\/aacrjournals.org\/cancerres\/article\/80\/16_Supplement\/CT190\/645131\/Abstract-CT190-A-multicenter-open-label-single-arm.","DOI":"10.1158\/1538-7445.AM2020-CT190"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"103454","DOI":"10.1016\/j.critrevonc.2021.103454","article-title":"Hype or hope\u2013Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced\/metastatic NSCLC ?","volume":"166","author":"Papini","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_112","unstructured":"(2022, April 15). Black Diamond Therapeutics IND for BDTX-1535 Cleared by FDA. Available online: https:\/\/www.precisiononcologynews.com\/cancer\/black-diamond-therapeutics-ind-bdtx-1535-cleared-fda#.YlxHYovMJPY."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1158\/1538-7445.AM2019-1326","article-title":"Abstract 1326: WSD0922: A BBB penetrable EGFR\/EGFRVIII inhibitor for the treatment of GBM and metastatic CNS tumor","volume":"79","author":"Zhong","year":"2019","journal-title":"Cancer Res."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Combs, S.E., Heeger, S., Haselmann, R., Edler, L., Debus, J., and Schulz-Ertner, D. (2006). Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)-Phase I\/II trial: Study protocol. BMC Cancer, 6.","DOI":"10.1186\/1471-2407-6-133"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1093\/annonc\/mdp032","article-title":"Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma","volume":"20","author":"Neyns","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_116","first-page":"508","article-title":"Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: A phase II trial","volume":"12","author":"Hasselbalch","year":"2010","journal-title":"Neuro-Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"504","DOI":"10.4161\/cbt.28021","article-title":"Nimotuzumab in combination with radiotherapy in high grade glioma patients: A single institution experience","volume":"15","author":"Solomon","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ejca.2014.12.019","article-title":"A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma","volume":"51","author":"Westphal","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1111\/ajco.12166","article-title":"Nimotuzumab, a humanized monoclonal antibody specific for the EGFR, in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma multiforme: First results in Chinese patients","volume":"12","author":"Wang","year":"2016","journal-title":"Asia. Pac. J. Clin. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.7150\/jca.30123","article-title":"Efficacy and safety of nimotuzumab in addition to radiotherapy and temozolomide for cerebral glioblastoma: A phase II multicenter clinical trial","volume":"10","author":"Du","year":"2019","journal-title":"J. Cancer"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2000124","DOI":"10.1002\/adtp.202000124","article-title":"Targeting Glioblastoma: Advances in Drug Delivery and Novel Therapeutic Approaches","volume":"4","author":"Yeini","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/neuonc\/noz222","article-title":"INTELLANCE 2\/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma","volume":"22","author":"Eoli","year":"2020","journal-title":"Neuro-Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3171\/2010.2.JNS091211","article-title":"A phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme","volume":"113","author":"Li","year":"2010","journal-title":"J. Neurosurg."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1158\/1535-7163.MCT-14-1078","article-title":"AMG 595, an anti-EGFRvIII antibody-drug conjugate, induces potent antitumor activity against EGFRvIII-expressing glioblastoma","volume":"14","author":"Hamblett","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00280-019-03879-2","article-title":"Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody\u2013drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII","volume":"84","author":"Rosenthal","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Oprita, A., Baloi, S., Staicu, G., and Alexandru, O. (2021). Updated Insights on EGFR Signaling Pathways in Glioma. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020587"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"7272","DOI":"10.1158\/1078-0432.CCR-08-0652","article-title":"Cancer Therapy: Preclinical Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3","volume":"14","author":"Zou","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11060-016-2092-2","article-title":"Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma","volume":"128","author":"Du","year":"2016","journal-title":"J. Neurooncol."},{"key":"ref_129","first-page":"115","article-title":"Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma","volume":"136","author":"Du","year":"2017","journal-title":"J. Neurooncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"e001146","DOI":"10.1136\/jitc-2020-001146","article-title":"Axitinib plus avelumab in the treatment of recurrent glioblastoma: A stratified","volume":"8","author":"Awada","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1200\/JCO.2009.26.3988","article-title":"Phase II Study of Cediranib, an Oral Pan\u2013Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma","volume":"28","author":"Batchelor","year":"2010","journal-title":"Am. Soc. Clin. Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1200\/JCO.2012.47.2464","article-title":"Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma","volume":"31","author":"Batchelor","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Brown, N., McBain, C., Nash, S., Hopkins, K., Sanhera, P., Saran, F., Phillips, M., Dungey, F., Clifton-hadley, L., and Wanek, K. (2016). Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent\/Progressive Glioblastoma. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0156369"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11060-010-0390-7","article-title":"Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide","volume":"103","author":"Gerstner","year":"2011","journal-title":"J. Neurooncol."},{"key":"ref_135","first-page":"348","article-title":"EORTC study 26041-22041: Phase I\/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787\/ZK222584 (PTK\/ZK) in newly diagnosed glioblastoma","volume":"6","author":"Brandes","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"e19226","DOI":"10.1097\/MD.0000000000019226","article-title":"Treatment response of bevacizumab combination chemotherapy in recurrent glioblastoma","volume":"99","author":"Huang","year":"2020","journal-title":"Medicine"},{"key":"ref_137","unstructured":"(2021, June 05). Refusal of a Change to the Marketing Authorisation for Avastin (Bevacizumab). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/smop\/questions-answers-refusal-change-marketing-authorisation-avastin-bevacizumab_en.pdf."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.repc.2013.01.006","article-title":"A prescri\u00e7\u00e3o fora das indica\u00e7\u00f5es aprovadas (off-label): Pr\u00e1tica e problemas","volume":"32","author":"Carneiro","year":"2013","journal-title":"Rev. Port. Cardiol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/jjco\/hys121","article-title":"Phase II Study of Single-agent Bevacizumab in Japanese Patients with Recurrent Malignant Glioma","volume":"42","author":"Nagane","year":"2012","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s12325-011-0007-3","article-title":"AVAglio: Phase 3 Trial of Bevacizumab Plus Temozolomide and Radiotherapy AVAglio: Phase 3 Trial of Bevacizumab Plus Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma Multiforme","volume":"28","author":"Chinot","year":"2011","journal-title":"Adv. Ther."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","article-title":"Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma","volume":"27","author":"Kreisl","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1634\/theoncologist.2017-0689","article-title":"Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG)","volume":"23","author":"Chinot","year":"2018","journal-title":"Oncologist"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Cruz, E., Silva, D., Mercier, M., Etienne-selloum, N., Dontenwill, M., and Choulier, L. (2021). A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials. Cancers, 13.","DOI":"10.3390\/cancers13081795"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s11060-009-9976-3","article-title":"Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide","volume":"96","author":"Dresemann","year":"2010","journal-title":"J. Neurooncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.1200\/JCO.2008.16.9235","article-title":"Phase II Study of Imatinib in Patients With Recurrent Gliomas of Various Histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group Study","volume":"26","author":"Raymond","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Alexandru, O., Sevastre, A., Castro, J., Artene, S., Tache, D.E., Purcaru, O.S., Sfredel, V., Tataranu, L.G., and Dricu, A. (2019). Platelet-Derived Growth Factor Receptor and Ionizing Radiation in High Grade Glioma Cell Lines. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20194663"},{"key":"ref_147","first-page":"7825","article-title":"Targeting the VEGF and PDGF signaling pathway in glioblastoma treatment","volume":"8","author":"Popescu","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1093\/neuonc\/nov011","article-title":"Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627) Andrew","volume":"17","author":"Lassman","year":"2015","journal-title":"Neuro-Oncol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1002\/cncr.32340","article-title":"A Phase 1 and Randomized, Placebo-Controlled Phase 2 Trial of Bevacizumab Plus Dasatinib in Patients With Recurrent Glioblastoma: Alliance\/North Central Cancer Treatment Group N0872","volume":"125","author":"Galanis","year":"2019","journal-title":"Cancer"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/stem.1328","article-title":"IGF1 Receptor Signaling Regulates Adaptive Radioprotection in Glioma Stem Cells","volume":"31","author":"Osuka","year":"2013","journal-title":"Stem Cells"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/neuonc\/nop008","article-title":"Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma","volume":"12","author":"Khan","year":"2010","journal-title":"Neuro-Oncol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"81501","DOI":"10.18632\/oncotarget.20662","article-title":"Phase I clinical trial of AXL1717 for treatment of relapsed malignant astrocytomas: Analysis of dose and response","volume":"8","author":"Aiken","year":"2017","journal-title":"Oncotarget"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s10637-015-0217-7","article-title":"Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2 weeks in patients with advanced solid tumors","volume":"33","author":"Higano","year":"2015","journal-title":"Investig. New Drugs"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/neuonc\/nou344","article-title":"Inhibition of intracerebral glioblastoma growth by targeting the insulin-like growth factor 1 receptor involves different context-dependent mechanisms","volume":"17","author":"Zamykal","year":"2015","journal-title":"Neuro-Oncol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11060-010-0502-4","article-title":"Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas","volume":"104","author":"Chaponis","year":"2011","journal-title":"J. Neurooncol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/neuonc\/2.3.151","article-title":"Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor SCH66336","volume":"2","author":"Glass","year":"2000","journal-title":"Neuro-Oncol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.pharep.2017.03.008","article-title":"Temozolomide and sorafenib as programmed cell death inducers of human glioma cells","volume":"69","author":"Badziul","year":"2017","journal-title":"Pharmacol. Rep."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1158\/1078-0432.CCR-13-0708","article-title":"Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial","volume":"19","author":"Galanis","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/cncr.31219","article-title":"Phase 1\/2 Trial of Temsirolimus and Sorafenib in the Treatment of Patients With Recurrent Glioblastoma: North Central Cancer Treatment Group Study\/Alliance N0572","volume":"124","author":"Schiff","year":"2018","journal-title":"Cancer"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/neuonc\/nos264","article-title":"Phase I\/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02","volume":"14","author":"Lee","year":"2012","journal-title":"Neuro-Oncol."},{"key":"ref_161","first-page":"3487","article-title":"Sorafenib Plus Daily Low Dose Temozolomide for Relapsed Glioblastoma: A Phase II Study","volume":"33","author":"Zustovich","year":"2013","journal-title":"Anticancer. Res."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1002\/cncr.25275","article-title":"Concurrent Radiotherapy and Temozolomide Followed by Temozolomide and Sorafenib in the First-Line Treatment of Patients With Glioblastoma Multiforme","volume":"116","author":"Hainsworth","year":"2010","journal-title":"Cancer"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11060-010-0217-6","article-title":"Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: Results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma","volume":"101","author":"Reardon","year":"2011","journal-title":"J. Neuro-Oncol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0308-1","article-title":"Anti-tumoral activity of sin-gle and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers","volume":"51","author":"Fondevila","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1470-2045(18)30675-2","article-title":"Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): A multicentre, open-label, randomised, controlled, phase 2 trial","volume":"20","author":"Lombardi","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"100263","DOI":"10.1016\/j.ctarc.2020.100263","article-title":"Regorafenib in glioblastoma recurrence: A case report","volume":"26","author":"Detti","year":"2021","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Lombardi, G., Caccese, M., Padovan, M., Cerretti, G., Pintacuda, G., Manara, R., Di Sarra, F., and Zagonel, V. (2021). Regorafenib in recurrent glioblastoma patients: A large and monocentric real-life study. Cancers, 13.","DOI":"10.3390\/cancers13184731"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.bbrc.2017.05.147","article-title":"Atorvastatin augments temozolomide\u2019s efficacy in glioblastoma via prenylation-dependent inhibition of Ras signaling","volume":"489","author":"Peng","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/annonc\/mdw367.32","article-title":"Phase II study of atorvastatin in combination with radiotherapy and temozolomide In patients with glioblastoma (ART): Interim analysis report","volume":"27","author":"Altwairgi","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"ix20","DOI":"10.1093\/annonc\/mdz419","article-title":"Phase II study of atorvastatin in combination with radiotherapy and temozolomide in patients with glioblastoma (ART): Final analysis report","volume":"30","author":"Altwairgi","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1200\/JCO.2017.35.15_suppl.2554","article-title":"Final Report of a Phase I Study of 2-Hydroxyoleic Acid (2OHOA) a Novel Sphingomyelin Synthase Activator in Patients (pt) with Advanced Solid Tumors (AST) Including Recurrent High Grade Gliomas (rHGG)","volume":"35","author":"Azaro","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_172","unstructured":"(2021, August 15). EMA EU\/3\/11\/916. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu311916."},{"key":"ref_173","unstructured":"(2021, August 15). A Clinical Phase IIB Trial with 2OHOA in Patients with Newly-Diagnosed Malignant Glioma. Available online: https:\/\/cordis.europa.eu\/project\/id\/755179."},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Degirmenci, U., Wang, M., and Hu, J. (2020). Targeting Aberrant RAS\/RAF\/MEK\/ERK Signaling for Cancer Therapy. Cells, 9.","DOI":"10.3390\/cells9010198"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11060-016-2158-1","article-title":"Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats","volume":"129","author":"Nethland","year":"2016","journal-title":"J. Neurooncol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"20189","DOI":"10.1038\/srep20189","article-title":"BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma","volume":"6","author":"Speranza","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1200\/JCO.18.01207","article-title":"Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial","volume":"37","author":"Wen","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/neuonc\/nop058","article-title":"Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma","volume":"12","author":"Koul","year":"2010","journal-title":"Neuro-Oncol."},{"key":"ref_179","first-page":"1270","article-title":"Phase II study of PX-866 in recurrent glioblastoma","volume":"17","author":"Pitz","year":"2015","journal-title":"Neuro-Oncol."},{"key":"ref_180","first-page":"1657","article-title":"Phase II Study of Bevacizumab and Temsirolimus Combination Therapy for Recurrent Glioblastoma Multiforme","volume":"33","author":"Lassen","year":"2013","journal-title":"Anticancer Res."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1158\/1078-0432.CCR-15-3153","article-title":"Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)","volume":"22","author":"Wick","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1093\/neuonc\/nou328","article-title":"A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K","volume":"17","author":"Ma","year":"2015","journal-title":"Neuro-Oncol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1200\/JCO.2009.23.2595","article-title":"Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma","volume":"28","author":"Wick","year":"2021","journal-title":"Am. Soc. Clin. Oncol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/neuonc\/nop042","article-title":"A phase I\/II trial of enzastaurin in patients with recurrent high-grade gliomas","volume":"12","author":"Kreisl","year":"2010","journal-title":"Neuro-Oncol."},{"key":"ref_185","first-page":"1415","article-title":"Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells\u2019 VEGF production and angiogenesis","volume":"119","author":"Bota","year":"2015","journal-title":"J. Neurooncol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s40880-019-0424-2","article-title":"Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1\u2013Survivin axis","volume":"39","author":"Tang","year":"2019","journal-title":"Cancer Commun."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41419-021-03535-9","article-title":"Ciclopirox and bortezomib synergistically inhibits glioblastoma multiforme growth via simultaneously enhancing JNK\/p38 MAPK and NF-\u03ba B signaling","volume":"12","author":"Su","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/neuonc\/nov299","article-title":"Marizomib activity as a single agent in malignant gliomas: Ability to cross the blood-brain barrier","volume":"18","author":"Di","year":"2016","journal-title":"Neuro-Oncol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41419-021-03927-x","article-title":"Marizomib sensitizes primary glioma cells to apoptosis induced by a latest-generation TRAIL receptor agonist","volume":"12","author":"Boccellato","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"157-e21","DOI":"10.1634\/theoncologist.2017-0501","article-title":"Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma","volume":"23","author":"Ghiaseddin","year":"2018","journal-title":"Oncologist"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/neuonc\/nor198","article-title":"Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: A north central cancer treatment group study","volume":"14","author":"Friday","year":"2012","journal-title":"Neuro-Oncol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1093\/neuonc\/nor017","article-title":"A phase I\/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03","volume":"13","author":"Iwamoto","year":"2011","journal-title":"Neuro-Oncol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1200\/JCO.2009.26.6650","article-title":"Phase I\/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma","volume":"28","author":"Stupp","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"5610","DOI":"10.1200\/JCO.2008.16.7510","article-title":"Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme","volume":"26","author":"Reardon","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/neuonc\/nou356","article-title":"Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: Results of the open-label, controlled, randomized phase II CORE study","volume":"17","author":"Nabors","year":"2015","journal-title":"Neuro-Oncol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S1470-2045(14)70379-1","article-title":"Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): A multicentre, randomised, open-label, phase 3 trial","volume":"15","author":"Stupp","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41379-018-0118-3","article-title":"Molecular characterization of cancers with NTRK gene fusions","volume":"32","author":"Gatalica","year":"2018","journal-title":"Mod. Pathol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/2159-8290.CD-18-0484","article-title":"Repotrectinib (TPX-0005) Is a Next-Generation ROS1\/TRK\/ALK Inhibitor That Potently Inhibits ROS1\/TRK\/ALK Solvent-Front Mutations","volume":"8","author":"Drilon","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1158\/2159-8290.CD-17-0507","article-title":"A next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion\u2013Positive Solid Tumors","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_200","doi-asserted-by":"crossref","unstructured":"Lassman, A., Sep\u00falveda-S\u00e1nchez, J., Cloughesy, T., Gil-Gil, J., Puduvalli, V., Raizer, J., De Vos, F., Wen, P., Butowski, N., and Clement, P. (2021, August 15). ACTR-33. Infigratinib (bgj398) in Patients with Recurrent Gliomas with Fibroblast Growth Factor Receptor (FGFR) Alterations. Available online: https:\/\/academic.oup.com\/neuro-oncology\/article-abstract\/21\/Supplement_6\/vi20\/5620107?redirectedFrom=fulltext.","DOI":"10.1093\/neuonc\/noz175.076"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4137\/CGM.S32801","article-title":"Synergistic Effects of Crizotinib and Temozolomide in Experimental FIG-ROS1 Fusion-Positive Glioblastoma","volume":"8","author":"Das","year":"2015","journal-title":"Cancer Growth Metastasis"},{"key":"ref_202","unstructured":"Mellinghoff, I.K., Cloughesy, T.F., Wen, P.Y., Taylor, J.W., Maher, E.A., Arrillaga-romany, I., Peters, K.B., Choi, C., Ellingson, B.M., and Lin, A.P. (2021, August 25). A Phase 1, Open-Label, Perioperative Study of Ivosidenib (AG-120) and Vorasidenib (AG-881) in Recurrent, IDH1-Mutant, Low-Grade Glioma: Results from Cohort 1. Available online: https:\/\/www.servier.us\/sites\/default\/files\/2021-04\/SNO19_phase1.pdf."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1158\/1535-7163.MCT-18-1349","article-title":"A Potent Blood\u2013Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model","volume":"19","author":"Machida","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1042\/BJ20091515","article-title":"AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7\u201310","volume":"530","author":"Ovens","year":"2010","journal-title":"Biochem. J."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1038\/s41598-017-04612-w","article-title":"Disruption of the monocarboxylate transporter-4-basigin interaction inhibits the hypoxic response, proliferation, and tumor progression","volume":"7","author":"Voss","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"603911","DOI":"10.3389\/fimmu.2020.603911","article-title":"Current Immunotherapies for Glioblastoma Multiforme","volume":"11","author":"Huang","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.neuron.2019.08.028","article-title":"Microglia\/brain macrophages as central drivers of brain tumor pathobiology","volume":"104","author":"Gutmann","year":"2020","journal-title":"Neuron"},{"key":"ref_208","doi-asserted-by":"crossref","unstructured":"De Leo, A., Ugolini, A., and Veglia, F. (2021). Myeloid Cells in Glioblastoma Microenvironment. Cells, 10.","DOI":"10.3390\/cells10010018"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1158\/0008-5472.CAN-18-3962","article-title":"The Tumor Microenvironment Innately Modulates Cancer Progression","volume":"79","author":"Hinshaw","year":"2020","journal-title":"Cancer Res."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1080\/21645515.2017.1303582","article-title":"Immune infiltration of tumor microenvironment following immunotherapy for glioblastoma multiforme","volume":"13","author":"Sokratous","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/annonc\/mdw168","article-title":"Targeting the tumor microenvironment: Removing obstruction to anticancer immune responses and immunotherapy","volume":"27","author":"Pitt","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_212","doi-asserted-by":"crossref","unstructured":"Baranska, J. (2020). Advances in Experimental Medicine and Biology: Glioma Signaling, Springer Nature. [2nd ed.].","DOI":"10.1007\/978-3-030-30651-9"},{"key":"ref_213","doi-asserted-by":"crossref","unstructured":"Desland, F.A., and Hormigo, A. (2020). The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy. Int. J. Mol. Sci, 21.","DOI":"10.3390\/ijms21197358"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ncl.2020.09.009","article-title":"What is New in Neuro-oncology?","volume":"39","author":"Thakkar","year":"2021","journal-title":"Neurol. Clin. NA"},{"key":"ref_215","doi-asserted-by":"crossref","unstructured":"Naing, A., and Hajjar, J. (2018). Advances in Experimental Medicine and Biology: Immunotherapy, Springer Nature.","DOI":"10.1007\/978-3-030-02505-2"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/14712598.2020.1713085","article-title":"Prospects of Biological and Synthetic Pharmacotherapies for Glioblastoma","volume":"20","author":"Altshuler","year":"2021","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_217","unstructured":"Bloch, O., Raizer, J.J., Lim, M., Sughrue, M., Komotar, R., AbrahamsDonald O\u2019Rourke, J., D\u2019Ambrosio, A., Bruce, J.N., and Parsa, A. (2021, July 25). Newly Diagnosed Glioblastoma Patients Treated with an Autologous Heat Shock Protein Peptide Vaccine: PD-L1 Expression and Response to Therapy. Available online: https:\/\/ascopubs.org\/doi\/abs\/10.1200\/jco.2015.33.15_suppl.2011."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/neuonc\/not203","article-title":"Heat-shock protein peptide complex\u201396 vaccination for recurrent glioblastoma: A phase II, single-arm trial","volume":"16","author":"Bloch","year":"2014","journal-title":"Neuro-Oncol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"vi29","DOI":"10.1093\/neuonc\/nox168.112","article-title":"ATIM-17. Early results of a multicenter phase I and open-label, randomized phase II study testing the toxicities and efficacy of MK-3475 (pembrolizumab) in combination with MRI-guided laser interstitial thermal therapy (LITT) in recurrent malignant glioma","volume":"29","author":"Campian","year":"2017","journal-title":"Neuro-Oncol."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1007\/s40265-019-01203-z","article-title":"Immunotherapy against gliomas-is the breakthrough near?","volume":"79","author":"Lukas","year":"2020","journal-title":"Drugs"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2020.02.002","article-title":"Immunotherapy for glioma: Current management and future application","volume":"476","author":"Xu","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3171\/2015.1.JNS141554","article-title":"Dendritic cell\u2013based immunotherapy targeting Wilms\u2019 tumor 1 in patients with recurrent malignant glioma","volume":"123","author":"Sakai","year":"2015","journal-title":"J. Neurosurg."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1158\/1078-0432.CCR-16-2057","article-title":"Long-term Survival in Glioblastoma with Cytomegalovirus pp65-targeted Vaccination","volume":"23","author":"Batich","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12967-018-1507-6","article-title":"First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma","volume":"16","author":"Liau","year":"2018","journal-title":"J. Transl. Med."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"621831","DOI":"10.3389\/fnmol.2021.621831","article-title":"Current Approaches for Glioma Gene Therapy and Virotherapy","volume":"14","author":"Banerjee","year":"2021","journal-title":"Front. Mol. Neurosci."},{"key":"ref_226","first-page":"35","article-title":"Prospects of immune checkpoint blockade and vaccine-based immunotherapy for glioblastoma","volume":"6","author":"Tietze","year":"2021","journal-title":"Innov. Surg. Sci."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41419-021-03568-0","article-title":"Immunotherapy for recurrent glioblastoma: Practical insights and challenging prospects","volume":"12","author":"Wang","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1080\/21645515.2020.1782692","article-title":"PD-1\/PD-L1 immune checkpoint inhibitors in glioblastoma: Clinical studies, challenges and potential","volume":"17","author":"Yang","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_229","unstructured":"Reardon, D.A., Nayak, L., Peters, K.B., Leigh Clarke, J., Jordan, J.T., Frederick De Groot, J., Leia Nghiemphu, P., Joseph Kaley, T., Colman, H., and Gaffey, S.C. (2021, July 25). Phase II Study of Pembrolizumab or Pembrolizumab Plus Bevacizumab for Recurrent Glioblastoma (rGBM) Patients. Available online: https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2018.36.15_suppl.2006."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"vi10","DOI":"10.1093\/neuonc\/noy148.033","article-title":"ATIM-38. Phase 2 Study to Evaluate the Clinical Efficacy and Safety of medi4736 (Durvalumab, Durva)+Bevacizumab (bev) in Bev-Na\u00efve Patients with Recurrent Glioblastoma (GBM)","volume":"20","author":"Reardon","year":"2018","journal-title":"Neuro-Oncol."},{"key":"ref_231","unstructured":"Reardon, D.A., Kaley, T.J., Dietrich, J., Clarke, J.L., Dunn, G., Lim, M., Cloughesy, T.F., Gan, H.K., Park, A.J., and Schwarzenberger, P. (2021, July 25). Phase II Study to Evaluate Safety and Efficacy of MEDI4736 (Durvalumab)+Radiotherapy in Patients with Newly Diagnosed Unmethylated MGMT Glioblastoma (New Unmeth GBM). Available online: https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2019.37.15_suppl.2032."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"578877","DOI":"10.3389\/fimmu.2020.578877","article-title":"Immune Checkpoint Targeted Therapy in Glioma: Status and Hopes","volume":"11","author":"Qi","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"592612","DOI":"10.3389\/fimmu.2020.592612","article-title":"Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma","volume":"11","author":"Zhang","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/sj.mt.6300108","article-title":"History of Oncolytic Viruses: Genesis to Genetic Engineering","volume":"15","author":"Kelly","year":"2007","journal-title":"Mol. Ther."},{"key":"ref_235","doi-asserted-by":"crossref","unstructured":"Varela-guruceaga, M., Tejada-sol, S., Garc, M., Fueyo, J., Gomez-manzano, C., Pati\u00f1o-garc, A., and Alonso, M.M. (2018). Oncolytic Viruses as Therapeutic Tools for Pediatric Brain Tumors. Cancers, 10.","DOI":"10.3390\/cancers10070226"},{"key":"ref_236","doi-asserted-by":"crossref","unstructured":"Rius-rocabert, S., and Garc, A. (2020). Oncolytic Virotherapy in Glioma Tumors. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21207604"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"E3","DOI":"10.3171\/2020.11.FOCUS20860","article-title":"Clinical trials using oncolytic viral therapy to treat adult glioblastoma: A progress report","volume":"50","author":"Lu","year":"2021","journal-title":"Neurosurg. Focus"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"12006","DOI":"10.1073\/pnas.1307935110","article-title":"Multifaceted Oncolytic Virus Therapy for Glioblastoma in an Immunocompetent Cancer Stem Cell Model","volume":"110","author":"Cheema","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"vi4","DOI":"10.1093\/neuonc\/noz175.014","article-title":"ATIM-14. Results of phase ii clinical trial of oncolytic herpes virus g47\u03b4 in patients with glioblastoma","volume":"11","author":"Todo","year":"2019","journal-title":"Neuro-Oncol."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma","volume":"36","author":"Lang","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"vi6","DOI":"10.1093\/neuonc\/noy148.019","article-title":"ATIM-24. interim results of a phase ii multicenter study of the conditionally replicative oncolytic adenovirus dnx-2401 with pembrolizumab (keytruda) for recurrent glioblastoma; captive study (keynote-192)","volume":"20","author":"Zadeh","year":"2018","journal-title":"Neuro-Oncol."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJMoa1716435","article-title":"Recurrent Glioblastoma Treated with Recombinant Poliovirus Annick","volume":"379","author":"Desjardins","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"341ra75","DOI":"10.1126\/scitranslmed.aad9784","article-title":"Phase 1 Trial of Vocimagene Amiretrorepvec and 5-Fluorocytosine for Recurrent High Grade Glioma","volume":"8","author":"Cloughesy","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1038\/mt.2012.83","article-title":"Design and Selection of Toca 511 for Clinical Use: Modified Retroviral Replicating Vector With Improved Stability and Gene Expression","volume":"20","author":"Perez","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_245","unstructured":"(2021, July 24). Tocagen Reports Results of Toca 5 Phase 3 Trial in Recurrent Brain Cancer. Available online: https:\/\/www.prnewswire.com\/news-releases\/tocagen-reports-results-of-toca-5-phase-3-trial-in-recurrent-brain-cancer-300916705.html."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/neuros\/nyaa584","article-title":"Chimeric Antigen Receptor T-Cell Therapy: Updates in Glioblastoma Treatment","volume":"88","author":"Feldman","year":"2021","journal-title":"Neurosurgery"},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s40265-022-01702-6","article-title":"Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date?","volume":"82","author":"Gatto","year":"2022","journal-title":"Drugs"},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ymthe.2017.10.002","article-title":"Optimization of IL13R\u03b12-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma","volume":"26","author":"Brown","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"715000","DOI":"10.3389\/fimmu.2021.715000","article-title":"Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13R\u03b12 and Suppress Malignant Glioma: A Preclinical Study","volume":"12","author":"Kim","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1158\/1078-0432.CCR-20-3760","article-title":"Opening of the blood\u2013brain barrier using low-intensity pulsed ultrasound enhances responses to immunotherapy in preclinical glioma models","volume":"27","author":"Sabbagh","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ErbB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3892\/ol.2012.872","article-title":"Molecular mechanisms of lung-specific toxicity induced by epidermal growth factor receptor tyrosine kinase inhibitors (Review)","volume":"4","author":"Sakao","year":"2012","journal-title":"Oncol. Lett."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"821663","DOI":"10.3389\/fcvm.2021.821663","article-title":"The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment","volume":"8","author":"Lin","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1161\/CIRCRESAHA.121.318223","article-title":"Heart Failure with Targeted Cancer Therapies: Mechanisms and Cardioprotection","volume":"128","author":"Hahn","year":"2021","journal-title":"Circ. Res."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1172\/JCI83416","article-title":"Tandem CAR T cells targeting HER2 and IL13R\u03b12 mitigate tumor antigen escape","volume":"126","author":"Hedge","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1093\/neuonc\/nox182","article-title":"Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma","volume":"20","author":"Bielamowicz","year":"2018","journal-title":"Neuro-Oncol."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat. Biotechnol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/10\/5351\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:09:12Z","timestamp":1760137752000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/10\/5351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,11]]},"references-count":257,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["ijms23105351"],"URL":"https:\/\/doi.org\/10.3390\/ijms23105351","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,11]]}}}